You are here: Industry Insights > SB-525

News List

Sangamo Announces Early Completion of Transfer to Pfizer of SB-525 americanpharmaceuticalreview
December 24, 2019
Sangamo Therapeutics announced the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug application (IND).
Sangamo announces promising early results for haemophilia A gene therapy pharmaceutical-technology
April 23, 2019
Sangamo announces promising early results for haemophilia A gene therapy.
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy americanpharmaceuticalreview
April 11, 2019
Sangamo, Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy.
Sangamo Announces Positive Preliminary Data from SB-525 Gene Therapy americanpharmaceuticalreview
August 10, 2018
Sangamo Therapeutics announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (Alta study).
Sangamo, Pfizer Announce First Patient Receives SB-525 Treatment in Clinical Trial expressbpd
August 28, 2017
Sangamo Therapeutics and Pfizer announced the first patient received treatment in the Phase 1/2 clinical trial (Alta trial) evaluating SB-525, an investigational gene therapy for patients with Hemophilia A, a rare genetic blood disorder.